The Relationship Between Gait Task Performance and Plasma Biomarkers for Alzheimer’s Disease in Cognitively Unimpaired Older Adults and Patients with Mild Cognitive Impairment

Step count may be more sensitive, compared to speed alone, in identifying those in preclinical AD stages. Gait metrics (speed and efficiency) played a key role as a clinical manifestation of early AD pathophysiology determined by blood-based biomarker concentration. Combining these assessments offers a multidimensional, cost-effective approach for preclinical-AD screening and potential early intervention.